These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 11823765)
1. Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. Gibler WB; Armstrong PW; Ohman EM; Weaver WD; Stebbins AL; Gore JM; Newby LK; Califf RM; Topol EJ; Ann Emerg Med; 2002 Feb; 39(2):123-30. PubMed ID: 11823765 [TBL] [Abstract][Full Text] [Related]
2. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872 [TBL] [Abstract][Full Text] [Related]
3. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819 [TBL] [Abstract][Full Text] [Related]
4. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
5. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929 [TBL] [Abstract][Full Text] [Related]
6. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. French JK; Edmond JJ; Gao W; White HD; Eikelboom JW Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722 [TBL] [Abstract][Full Text] [Related]
8. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. Newby LK; Rutsch WR; Califf RM; Simoons ML; Aylward PE; Armstrong PW; Woodlief LH; Lee KL; Topol EJ; Van de Werf F J Am Coll Cardiol; 1996 Jun; 27(7):1646-55. PubMed ID: 8636549 [TBL] [Abstract][Full Text] [Related]
9. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645 [TBL] [Abstract][Full Text] [Related]
10. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. Brieger DB; Mak KH; White HD; Kleiman NS; Miller DP; Vahanian A; Ross AM; Califf RM; Topol EJ Am J Cardiol; 1998 Feb; 81(3):282-7. PubMed ID: 9468068 [TBL] [Abstract][Full Text] [Related]
11. Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. Chang WC; Fu Y; Ohman EM; Gupta M; Morris A; Roth SN; Granger CB; Califf RM; Topol EJ; Mark DB; Armstrong PW Can J Cardiol; 2000 Oct; 16(10):1231-9. PubMed ID: 11064297 [TBL] [Abstract][Full Text] [Related]
12. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Newby LK; Califf RM; Guerci A; Weaver WD; Col J; Horgan JH; Mark DB; Stebbins A; Van de Werf F; Gore JM; Topol EJ J Am Coll Cardiol; 1996 Mar; 27(3):625-32. PubMed ID: 8606274 [TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825 [TBL] [Abstract][Full Text] [Related]
14. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Cohen MG; Granger CB; Ohman EM; Stebbins AL; Grinfeld LR; Cagide AM; Elizari MV; Betriu A; Kong DF; Topol EJ; Califf RM J Am Coll Cardiol; 1999 Nov; 34(6):1729-37. PubMed ID: 10577563 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Moen EK; Asher CR; Miller DP; Weaver WD; White HD; Califf RM; Topol EJ J Womens Health; 1997 Jun; 6(3):285-93. PubMed ID: 9201663 [TBL] [Abstract][Full Text] [Related]
16. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction. Gillis JC; Goa KL Pharmacoeconomics; 1996 Sep; 10(3):281-310. PubMed ID: 10163575 [TBL] [Abstract][Full Text] [Related]
17. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase. Smith BJ J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811 [TBL] [Abstract][Full Text] [Related]
18. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973 [TBL] [Abstract][Full Text] [Related]
19. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348 [TBL] [Abstract][Full Text] [Related]
20. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Singh N; Mironov D; Armstrong PW; Ross AM; Langer A Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]